New plasminogen activators: A clinical review

Clinical Cardiology

Volumn 22, Issue 3, 1999, Pages 165-171

  Ross, Allan M ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Acute myocardial infarction; Plasminogen activators; Thrombolysis; TNK tissue plasminogen activator

Indexed keywords

ALTEPLASE; DESMOTEPLASE; LANOTEPLASE; RETEPLASE; SARUPLASE; STAPHYLOKINASE; TNK TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; HEART MUSCLE REPERFUSION; REVIEW; SURVIVAL RATE;

EID: 0033044862     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960220303     Document Type: Review

References (54)

1. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682
2. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622
3. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D. Betriu A, Califf RM, Ross AM, for the GUSTO-I Investigators: Link between the angiographic substudy and mortality outcomes in the large randomized trial of myocardial reperfusion. Circulation 1995;91:1923-1928
4. Ross AM, Coyne K, Moreya E, Reiner JS, Greenhouse SW, Walker PL, Simoons ML, Draoui YC, Califf RM, Topol EJ, Van de Werf F, Lundergan CF, for the GUSTO-I Angiographic Investigators: Extended mortality benefit of early postinfarction reperfusion. Circulation 1998;97:1549-1556
5. Collen D: Thrombolytic therapy. Thromb Haemost 1997;78(1): 742-746
6. Lefkovits J, Topol EJ: Future directions in thrombolysis for myocardial infarction: What are the unanswered questions? Coron Art Dis 1994;5:306-316
7. Huber K, Maurer G: Thrombolytic therapy in acute myocardial infarction. Sem Thromb Hemost I 996;22:15-26
8. Van de Werf F: TNK-t-PA: Results of the phase II trials. TIMI 10B and ASSENT-I. Presented at the New Developments in Thrombolytic and Antithrombotic Therapy Satellite Symposium at the XIX Congress of the European Society of Cardiology, August 24-28, 1997, Stockholm, Sweden
9. Ross AM: New thrombolytic agents. J Intervent Cardiol 1997; 10:395-399
10. Smalling RW: Molecular biology of plasminogen activators: What are the clinical implications of drug design? Am J Cardiol 1996; 78(suppl 12A):2-7
11. Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, Seals A, and the RAPID Investigators: More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91: 2725-2732
12. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, Chernoff R, Christie LG, Feldman RL, Seals AA, Weaver WD for the RAPID II Investigators: Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-898
13. The GUSTO III Investigators: Comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337: 1118-1123
14. White HD: Thrombolytic therapy and equivalence trials. J Am Coll Cardiol 1998;31:494-496
15. Gurbel PA, Serebruany VL, Shustov AR, Bahr RD, Carpo C, Ohman EM, Topol FJ for the GUSTO-III Investigators: Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol 1998;31:1466-1473
16. Stringer KA: Biochemical and pharmacologic comparison of thrombolytic agents. Pharmacotherapy 1996;16(5 pt. 2) 119S-126S
17. Koster RW, Cohen AF, Hopkins GR, Beier H, Gunzler WA, van der Wouw PA: Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost 1994;72:740-744
18. Cutler D, Bode C, Runge MS: The promise of new genetically engineered plasminogen activators. J Vasc Intervent Radiol 1995; 6:3S-7S
19. Sasahara AA, Barker WM, Weaver WD, Hartmann J, Anderson JL, Sudhakar Reddy P, Villiard EM: Clinical studies with the new glycosylated recombinant prourokinase. J Vase Intervent Radiol 1995;6(suppl):84S-93S
20. Spiecker M, Meyer J: Prourokinase für die Infarkttherapie (prourokinase for treatment of acute myocardial infarction). Herz 1994; 19:326-335
21. Vermeer F, Bär F, Windeler J, Schenkel W: Saruplase, a new fibrin specific thrombolytic agent: Final results of the PASS study (1689 patients). Circulation 1993;88:I-292
22. Tebbe U, Windeler J, Boesl I, Hoffmann H, Wojcik J, Ashmawy M, Schwarz ER, von Lewis of Menar P, Rosemeyer P, Hopkins G, Barth H on behalf of the LIMITS Study Group: Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: Influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis with Saruplase. J Am Coll Cordiol 1995;26:365-373
23. Bär FW, Meyer J, Vermeer F, Michels R, Charbonnier B, Haerten K, Spieker M, Macaya C, Hanssen M, Heras M, Boland JP, Morice M-C, Dunn FG, Uebis R, Hamm C, Ayzenberg O, Strupp G, Withagen AJ, Klein W, Windeler J, Hopkins G, Barth H, von Fisenne MJM for the SESAM Study Group: Comparison of saruplase and alteplase in acute myocardial infarction. Am J Cardiol 1997;79: 727-732
24. PRIMI Trial Study Group: Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989;1:863-868
25. Tebbe U, Michels R, Adgey J, Boland J, Caspi A, Charbonnier B, Windeler J, Barth H, Groves R, Hopkins GR, Fennel W, Betriu A, Ruda M, Mlczoch J: Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS equivalence trial. J Am Coll Cardiol 1998;31: 487-493
26. Bode C, Peter K, Nordt T, Kohler B, Moser M, Ruef J, Runge MS: New developments in thrombolytic therapy. Fibrin Proteol 1997; 11(suppl 1):109-114
27. Bode C, Runge MS, Schonermark S. Eberle T, Newell JB, Kubler W, Haber E: Conjugation to an antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Cirrulation 1990;81:1974-1980
28. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, Etcheverry T, Botstein D, Bennett WF: A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994;91:3670-3674
29. Topol EJ: Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998;97:211-218
30. DeMarco E, Rebuzzi AG, Quaranta G, ven de Greef W, Kol A, Biasucci LG, Maseri A, Andreotti F: Lack of procoagulant effect after TNK-plasminogen activator in patients with acute myocardial infarction. Eur Heart J 1998; 19(suppl):5
31. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E, and the TIMI 10A Investigators: TNK-tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95:351-356
32. Cannon CP, McCabe CH, Gibson CM, Adgey AJ, Schweiger MJ, Sequeira RF, Frey M, Mueller HS, McCluskey ER, Fox NL, Van de Werf F, Braunwald E, Weaver WD: TNK-tissue plasminogen activator compared with front-loaded tissue plasminogen activator in acute myocardial infarction: Primary results of the TIMI 10B trial. Circulation 1997;96(8)(suppl I):I-206
33. Giugliano RP, Cannon CP, McCabe CH, Van de Werf F, Braunwald E: Lower dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage: Results from TIMI 10B and AS-SENT I. Circulation 1997;96(8)(suppl I):I-535
34. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, McCabe C, Raymond L, Fortin T, Poole WK, Braunwald E, for the TIMI 4 Study Group: TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 1996;93: 879-888
35. Gibson CM: A randomized prospective comparison of t-PA with TNK using the TIMI frame count: Results of TIMI-10B. Presented at the 70th Scientific Sessions of the American Heart Association; November 9-12, 1997; Orlando, Florida
36. Gibson CM, Cannon CP, McCabe C, Van de Werf F, Braunwald E: A randomized prospective comparison of TPA with TNK using the TIMI frame count: Results of TIMI 10B. Circulation 1997;96(8) (suppl I):I330-I331
37. Lerakis S, Stouffer GA, Runge MS: New thrombolytics: What is under development? Bio Drugs 1997;8(1):24-32
38. Ogata N, Ogata Y, Hokamaki J, Araki H, Morikami Y, Numata Y: Serial changes of plasminogen activator inhibitor activity in thrombolytic therapy for acute myocardial infarction: Comparison between thrombolytic therapies with mutant TPA (lanoteplase/BMS-200980) and recombinant TPA (alteplase). Circulation 1996;94(8) (suppl I):I-89
39. Thadani U: Lanoteplase: The InTIME Study. Presented at Myocardial Reperfusion X: Concepts and Controversies; Satellite symposium at the 46th Annual Scientific Session of the American College of Cardiology; March 14,1997; Anaheim, California
40. Liao WC, Beierle FA, Stouffer BC, Dockens RC, Abbud ZA, Tay LK, Knaus DM, Raymond RH, Chew PH, Kostis JB: Single bolus regiment of lanoteplase (nPA) in acute myocardial infarction: Pharmacokinetic evaluation from InTime-I study. Circulation 1997;96(8)(suppl I):I-260-261
41. Lundergan CF, Reiner JS. McCarthy WF, Coyne KS, Califf RM, Ross AM, for the GUSTO-I Investigators: Clinical predictors of early infarct related artery patency following thrombolytic therapy: Importance of body weight, smoking history, infarct related artery and choice of thrombolytic regimen: The GUSTO-I experience. J Am Coll Cardiol 1998:32(3);641-647
42. Collen D, Stock L, LaCroix H. Suy R, Vanderscheuren S: Recombinant staphylokinase variants with altered immunoreactivity IV: Identification of variants with reduced antibody induction but intact potency. Circulation 1997;95:463-472
43. Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D, Van de Werf F, for the STAR Trial group: A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995;92: 2044-2049
44. Gulba DC, Bode C, Runge MS, Huber K: Thrombolytic agents -an overview. Ann Hematol 1996;73(suppl I):S9-S27
45. Collen D: Staphylokinase: A potent, uniquely fibrin-selective thrombolytic agent. Nature Med 1998;4(3):279-284
46. Collen D, Vanderschueren S, Van de Werf F: Fibrin-selective thrombolytic therapy with recombinant staphylokinase. Haemostasis 1996;26(suppl 4):294-300
47. Collen D, Moreau H, Stock L, Vanderscheuren S: Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction. Circulation 1996;94: 207-216
48. Van de Werf F: New fibrinolytic landscape (TNK, nPA, staphylokinase). Presented at Myocardial Reperfusion XI: Concepts and Controversies; Satellite symposium at the 46th Annual Scientific Session of the American College of Cardiology; March 28,1998; Atlanta, Georgia
49. Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang S, Tung J, Mark GE, Shebuski RJ: Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991;84:244-253
50. Mellott MJ, Stabilito II, Holahan MA, Cuca GC, Wang S, Li P, Barrett JS, Lynch JJ, Gardell SJ: Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscler Thromb 1992;12:212-221
51. Montoney M, Gardell SJ, Marder VJ: Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 1995;91:1540-1544
52. Antman EM, Giugliano RP, McCabe CH, Gibson M, Adgey AJJ, Ghali M, Coussement P, Anderson KM, Scherer J, Van de Werf F, Braunwald E, for the TIMI 14 Investigators: Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: Results of TIMI 14 trial. J Am Coll Cardiol 1998;31(suppl):191A
53. Ross AM: The Plasminogen Activator-Angioplasty Compatibility Trial (PACT). Presented at Thrombolysis and Interventional Therapy in Acute Myocardial Infarction. Satellite symposium at the 70th Scientific Sessions of the American Heart Association; November 8, 1997;Orlando, Florida
54. Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W, Limbourg P, Merx W, Haerten K: Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 1992;19: 885-891